Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $117
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $102 to $117.
Follow the latest CG Oncology, Inc. (CGON) news and market headlines alongside the live CGON price. Stay informed on what's moving CGON.
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $102 to $117.
JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $96 to $113.
Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $85 to $100.
RBC Capital analyst Leonid Timashev downgrades CG Oncology (NASDAQ:CGON) from Outperform to Sector Perform and raises the price target from $80 to $97.
Wall Street analysts raised price targets for CG Oncology, Viatris, Rubrik, Allarity, IDACORP, Tyson Foods and Range Resources.
Wedbush analyst Robert Driscoll maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $84 to $91.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $100 to $115.
CG Oncology reports Phase 3 data showing cretostimogene cuts bladder cancer recurrence risk by 68%, advancing two 2027 BLA filings.
U.S. stocks fell Monday as tech slid and manufacturing sentiment weakened; oil, gold and silver also declined, while TELUS and H World surged.
U.S. stocks fell, but H World Group surged 9.3% on strong Q3 results and raised guidance; several other stocks posted notable gains.
Topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC, following complete tumor
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to CGON, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.